Orchestrating the Tumor Microenvironment to Improve Survival for Patients with Pancreatic Cancer

Cancer Journal (United States)

Volumn 21, Issue 4, 2015, Pages 299-306

  Whatcott, Clifford J ^a   Han, Haiyong ^a   Von Hoff, Daniel D ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Extracellular matrix; metastasis; pancreatic cancer; tumor microenvironment

Indexed keywords

COLLAGEN; GEMCITABINE; HYALURONIC ACID; OSTEONECTIN; PACLITAXEL; STRUCTURAL PROTEIN; TRANSFORMING GROWTH FACTOR BETA; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; HYALURONOGLUCOSAMINIDASE; MACROGOL DERIVATIVE; SPARC PROTEIN, HUMAN;

CANCER PATIENT; CANCER SURVIVAL; CELL ADHESION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; NEUTROPHIL; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; FIBROSIS; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; SURVIVAL RATE;

ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; COLLAGEN; DEOXYCYTIDINE; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; MOLECULAR TARGETED THERAPY; OSTEONECTIN; PACLITAXEL; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; SURVIVAL RATE; TUMOR MICROENVIRONMENT;

EID: 84938566955     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000140     Document Type: Review

References (103)

1. Siegel RL,MillerKD, Jemal A. Cancer statistics, 2015. CACancer J Clin. 2015;65:5-29.
2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
3. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-2921.
4. Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497:633-637.
5. Kamphorst JJ, Cross JR, Fan J, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A. 2013;110:8882-8887.
6. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037.
7. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369: 1691-1703.
8. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6:1186-1197.
9. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583-592.
10. Netti PA, Berk DA, SwartzMA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60:2497-2503.
11. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814-2823.
12. Houten L, Reilley AA. An investigation of the cause of death fromcancer. J Surg Oncol. 1980;13:111-116.
13. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205-2218.
14. Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy responsewithout increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013; 110:12325-12330.
15. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418-429.
16. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nabpaclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554.
17. Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015.
18. Faouzi S, Le BailB,Neaud V, et al.Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol. 1999;30:275-284.
19. Yen TW, Aardal NP, BronnerMP, et al.Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery. 2002;131:129-134.
20. Stylianopoulos T, Martin JD, Chauhan VP, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A. 2012;109:15101-15108.
21. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461.
22. Duda DG, Duyverman AM, Kohno M, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010;107:21677-21682.
23. Bertrand P, Girard N, Delpech B, et al. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas. Int J Cancer. 1992;52:1-6.
24. Anttila MA, Tammi RH, Tammi MI, et al. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res. 2000;60:150-155.
25. Auvinen P, Tammi R, Parkkinen J, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol. 2000;156:529-536.
26. Setala LP, TammiMI, Tammi RH, et al. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer. 1999;79:1133-1138.
27. Theocharis AD, Tsara ME, Papageorgacopoulou N, et al. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta. 2000;1502:201-206.
28. Gebhardt C, Averbeck M, Diedenhofen N, et al. Dermal hyaluronan is rapidly reduced by topical treatment with glucocorticoids. J Invest Dermatol. 2010;130:141-149.
29. Yoshihara S, Kon A, Kudo D, et al. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett. 2005;579:2722-2726.
30. Nagy N, Kuipers HF, Frymoyer AR, et al. 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol. 2015;6:123.
31. Yates TJ, Lopez LE, Lokeshwar SD, et al. Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer. J Natl Cancer Inst. 2015;107.
32. Kohno N, Ohnuma T, Truog P. Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality. J Cancer Res Clin Oncol. 1994;120:293-297.
33. Beckenlehner K, Bannke S, Spruss T, et al. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J Cancer Res Clin Oncol. 1992;118:591-596.
34. Muckenschnabel I, Bernhardt G, Spruss T, et al. Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice. Cancer Chemother Pharmacol. 1996; 38:88-94.
35. Baumgartner G. The impact of extracellular matrix on chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 1998;131:1-2.
36. Smith KJ, Skelton HG, Turiansky G, et al. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol. 1997;36:239-242.
37. Pillwein K, Fuiko R, Slavc I, et al. Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett. 1998;131:101-108.
38. Maier U, Baumgartner G. Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial. J Urol. 1989;141:529-530.
39. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs. 2007;30:293-299.
40. Shepard HM, Frost GI, Rybak ME, et al. Targeting hyaluronan (HA) in tumor stroma: translational evaluation of pegylated hyaluronidase (PEGPH20, P) in animal models and patients (PTS) with advanced solid tumors. Presented at the 2010 ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer October 18-20, 2010; Hollywood, Florida; abstract 114.
41. Hingorani SR, Harris WP, Hendifar AE, et al. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: interim results of a randomized phase II study. J Clin Oncol. 2015;33 (suppl):Abstr 4006.
42. Chauhan VP, Boucher Y, Ferrone CR, et al. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell. 2014;26:14-15.
43. DelGiorno KE, CarlsonMA, Osgood R, et al. Response to Chauhan et al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning. Cancer Cell. 2014;26:16-17.
44. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 2013;108:1-8.
45. Dangi-Garimella S, Krantz SB, BarronMR, et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011;71:1019-1028.
46. Diop-Frimpong B, Chauhan VP, Krane S, et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A. 2011;108:2909-2914.
47. Shields MA, Dangi-Garimella S, Krantz SB, et al. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem. 2011;286:10495-10504.
48. Shintani Y, Hollingsworth MA, Wheelock MJ, et al. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res. 2006; 66:11745-11753.
49. Brown E, McKee T, diTomaso E, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003;9:796-800.
50. MiyamotoH,Murakami T, TsuchidaK, et al. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 2004;28:38-44.
51. Rivera LB, Carbon JG, Aguilera K, et al. Strategies to combat hypoxiadriven PDAC invasion after antiangiogenic therapy. Presented at the AACR Pancreatic Cancer Special Conference; 2012; abstract A24.
52. Rasheed ZA, Jung C, Huang A, et al. The extracellular matrix regulates pancreatic cancer stem cell function via focal adhesion kinase signaling. Presented at the AACR Pancreatic Cancer Special Conference; 2012; abstract A70.
53. TadaM, Omata M, Moses HL, et al. The exploration of novel strategy for treatment of pancreatic ductal adenocarcinoma targeting tumormicroenvironment. Presented at the AACR Pancreatic Cancer Special Conference; 2012; abstract A85.
54. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008;22:276-284.
55. Grzesiak JJ, Ho JC, Moossa AR, et al. The integrin-extracellular matrix axis in pancreatic cancer. Pancreas. 2007;35:293-301.
56. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816-826.
57. Linder S, Castanos-Velez E, von Rosen A, et al. Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology. 2001;48:1321-1327.
58. Erkan M, Michalski CW, Rieder S, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6:1155-1161.
59. Suetsugu A, Snyder CS, Moriwaki H, et al. Imaging the interaction of pancreatic cancer and stellate cells in the tumor microenvironment during metastasis. Anticancer Res. 2015;35:2545-2551.
60. Shields MA, Ebine K, Sahai V, et al. Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol Cancer Res. 2013;11:1078-1087.
61. Bierie B,Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506-520.
62. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002;12:22-29.
63. Naber HP, ten Dijke P, Pardali E. Role of TGF-beta in the tumor stroma. Curr Cancer Drug Targets. 2008;8:466-472.
64. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
65. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15:4674-4679.
66. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-1813.
67. Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factorbeta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.Mol Biol Cell. 2001;12:27-36.
68. Mulder KM, Morris SL. Activation of p21ras by transforming growth factor beta in epithelial cells. J Biol Chem. 1992;267:5029-5031.
69. Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of theMAPKKK family as a potential mediator of TGF-beta signal transduction. Science. 1995;270:2008-2011.
70. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem. 2005; 280:10870-10876.
71. Muraoka-Cook RS, Kurokawa H, Koh Y, et al. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res. 2004;64:9002-9011.
72. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 2002;109:1551-1559.
73. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice againstmetastasiswithout adverse side effects. J Clin Invest. 2002;109:1607-1615.
74. Zion O, Genin O, Kawada N, et al. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas. 2009;38:427-435.
75. Adrian K, Strouch MJ, Zeng Q, et al. Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. Cancer Res. 2009;69:9169-9174.
76. Haddad Y, Choi W, McConkey DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res. 2009;15:532-542.
77. Postigo AA. Opposing functions of ZEB proteins in the regulation of the TGFbeta/BMP signaling pathway. EMBO J. 2003;22:2443-2452.
78. Gold DV, Karanjawala Z, Modrak DE, et al. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res. 2007; 13:7380-7387.
79. Gold DV, Modrak DE, Ying Z, et al. NewMUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006;24:252-258.
80. Ocean AJ, Pennington KL, Guarino MJ, et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer. 2012;118:5497-5506.
81. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oilbased paclitaxel in women with breast cancer. J Clin Oncol. 2005;23: 7794-7803.
82. Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:852-861.
83. Yardley DA, Daniel BR, Inhorn RC, et al. SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). J Clin Oncol. 2010;28:15s, 2010; (suppl; abstr 10574) 28, 15s (suppl; abstr 10574).
84. Guweidhi A, Kleeff J, Adwan H, et al. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg. 2005;242:224-234.
85. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-325.
86. Watkins G, Douglas-Jones A, Bryce R, et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005;72:267-272.
87. Koukourakis MI,GiatromanolakiA, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 2003;63:5376-5380.
88. Massi D, Franchi A, Borgognoni L, et al. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999;30:339-344.
89. Goldstein D, Maraghi RHE, Hammel P, et al. Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2014;32:2014; (suppl 3; abstr 178) 32, abstr 178.
90. Hidalgo M, Plaza C, Illei P, et al. SPARC analysis in the phase IIIMPACT trial of nab-paclitaxel (nab-p) plus gemcitabine (gem) vs gemalone for patients with metastatic pancreatic cancer. Ann Oncol. 2014;25(suppl-2): ii105-ii117.
91. Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109:926-933.
92. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719-734.
93. Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735-747.
94. ShermanMH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159:80-93.
95. Stromnes IM, Brockenbrough JS, Izeradjene K, et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63:1769-1781.
96. De Carvalho DD, You JS, Jones PA. DNA methylation and cellular reprogramming. Trends Cell Biol. 2010;20:609-617.
97. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30-39.
98. Ischenko I, Petrenko O, HaymanMJ. Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc Natl Acad Sci U S A. 2014;111:3466-3471.
99. Sahai V, Kumar K, Knab LM, et al. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther. 2014;13:1907-1917.
100. Chugh R, Sangwan V, Patil SP, et al. A preclinical evaluation ofminnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012; 4:156ra139.
101. Greeno E, Borazanci E, Gockerman J, et al. Phase I dose escalation and pharmokinetic study of 14-O-phosphonooxymethyltriptolide. Presented at the AACR 2015 Annual Meeting; Philadelphia, PA; 2015; abstract CT207.
102. Ali K, Soond DR, Pineiro R, et al. Inactivation of PI(3)Kp110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014; 510:407-411.
103. Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266-4276.